Helius Medical Technologies, Inc. (NASDAQ:HSDT) Sees Significant Increase in Short Interest

Helius Medical Technologies, Inc. (NASDAQ:HSDTGet Rating) saw a significant growth in short interest in December. As of December 30th, there was short interest totalling 582,000 shares, a growth of 58.7% from the December 15th total of 366,700 shares. Based on an average daily trading volume, of 760,400 shares, the short-interest ratio is currently 0.8 days.

Wall Street Analysts Forecast Growth

Separately, Maxim Group began coverage on shares of Helius Medical Technologies in a research note on Tuesday, December 20th. They set a “buy” rating for the company.

Helius Medical Technologies Trading Up 2.8 %

HSDT opened at $0.37 on Friday. The firm has a market capitalization of $10.35 million, a PE ratio of -0.10 and a beta of 1.02. The firm’s 50-day moving average price is $0.30 and its 200 day moving average price is $0.49. Helius Medical Technologies has a twelve month low of $0.20 and a twelve month high of $4.76.

Helius Medical Technologies (NASDAQ:HSDTGet Rating) last posted its earnings results on Monday, November 14th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.12. The firm had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.13 million. Helius Medical Technologies had a negative net margin of 1,741.55% and a negative return on equity of 148.27%. As a group, analysts predict that Helius Medical Technologies will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of Helius Medical Technologies

An institutional investor recently raised its position in Helius Medical Technologies stock. BlackRock Inc. raised its holdings in Helius Medical Technologies, Inc. (NASDAQ:HSDTGet Rating) by 8,297.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 255,381 shares of the company’s stock after acquiring an additional 252,340 shares during the quarter. BlackRock Inc. owned 0.91% of Helius Medical Technologies worth $71,000 as of its most recent filing with the Securities and Exchange Commission. 11.77% of the stock is currently owned by institutional investors.

About Helius Medical Technologies

(Get Rating)

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.

Read More

Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.